P95 BV Acquires Assign DMB

September 5, 2024

P95 BV, a Belgium-based epidemiology and clinical solutions provider backed by Ampersand Capital Partners, has acquired Assign DMB, an Innsbruck, Austria-based clinical research organisation specializing in clinical data management and biostatistics. The deal expands P95's capabilities and capacity to run clinical and non-interventional studies—particularly in vaccines and infectious diseases—and broadens its presence in Europe and globally.

Buyers
P95 BV, Ampersand Capital Partners
Targets
Assign DMB
Platforms
P95 BV
Location
Tyrol, Austria
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.